Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000522865 | SCV000618700 | uncertain significance | not provided | 2017-07-03 | criteria provided, single submitter | clinical testing | The E1298K variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The E1298K variant is observed in 1/9303 (0.01%) alleles from individuals of Latino background, including 1 hemizygous individual in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The E1298K variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is not conserved. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. In summary, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
Labcorp Genetics |
RCV001314423 | SCV001504957 | likely benign | Methylmalonic acidemia with homocystinuria, type cblX | 2024-02-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002527603 | SCV003706879 | uncertain significance | Inborn genetic diseases | 2022-04-12 | criteria provided, single submitter | clinical testing | The c.3892G>A (p.E1298K) alteration is located in exon 17 (coding exon 17) of the HCFC1 gene. This alteration results from a G to A substitution at nucleotide position 3892, causing the glutamic acid (E) at amino acid position 1298 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |